{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:30:39Z","timestamp":1773225039384,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T00:00:00Z","timestamp":1183420800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Use of topical corticosteroids for the treatment of pityriasis alba is limited by their potential side\u2010effects, such as skin atrophy especially with long\u2010term use on the face. Pimecrolimus cream 1% is a topical calcineurin inhibitor that has anti\u2010inflammatory properties, lacks the cutaneous side\u2010effects associated with steroids, and provide a potential benefit for the treatment of pityriasis alba.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> This 10\u2010patient, prospective, single\u2010arm, open\u2010label, single\u2010center, 12\u2010week, investigator\u2010initiated proof of concept study assessed the efficacy, safety, and patient acceptance of pimecrolimus cream 1% twice daily. In addition to pimecrolimus cream, patients used facial emollient containing SPF 15 sunscreen and mild soap\u2010free cleanser. Efficacy assessments were Investigator Global Assessment (IGA) of disease severity and evaluation of uneven skin color, scaling, eczema, follicular keratosis, and pruritus. All efficacy assessments were reported on a 4\u2010point scale (0\u00a0=\u00a0none to 3\u00a0=\u00a0severe).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Of the 10\u00a0patients enrolled (aged: 12\u201335\u00a0years), all had intensive sun\u2010exposure, 90% had skin type\u00a0IV\u2013V, and 80% completed the 12\u2010week treatment. At baseline, mean IGA was 1.20 (mild\u2013moderate), uneven skin color was 2.3 (moderate\u2013severe) and scaling was 1.2 (mild). IGA decreased to 0.25 by week 12, uneven skin color improved by week 3 with near complete resolution by week 12 (mean\u00a0=\u00a00.38) and scaling resolved at week 3. Pruritus, eczema, and follicular keratosis remained at low levels from baseline throughout the course of the study. Patients consistently reported satisfaction with the treatment (\u201csatisfied\u201d or \u201cvery satisfied\u201d). No adverse events were reported.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Pimecrolimus cream 1% may represent an alternative for the treatment of pityriasis alba.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2007.03145.x","type":"journal-article","created":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T11:03:02Z","timestamp":1183460582000},"page":"700-705","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["An Exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba"],"prefix":"10.1111","volume":"46","author":[{"given":"Wayne H.","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calogera L.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Parneix\u2010Spake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,7,3]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"268","article-title":"Partial depigmentation chiefly of the face in Negro Children","volume":"7","author":"Fox H","year":"1923","journal-title":"Arch Derma Syphiol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1956.01550040070010"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1960.01580020025003"},{"key":"e_1_2_6_5_2","first-page":"50","article-title":"Evaluation and relevance of atopic basic and minor features in patients with atopic dermatitis and in the general population","volume":"144","author":"Diepgen TL","year":"1989","journal-title":"Acta Derm Venereol (Stockh) Supplement"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1995.tb00156.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)38164-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555924447"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb01401.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1961.01580120027005"},{"key":"e_1_2_6_11_2","first-page":"21","article-title":"Pityriasis alba","volume":"76","author":"Lin RL","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1963.01590210030004"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.04934.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(97)00020-5"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.29066"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050343"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.116865"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122187"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.65"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long\u2010term management of atopic dermatitis in children","volume":"110","author":"Wahn U","year":"2002","journal-title":"Pediatrics"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078462"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"key":"e_1_2_6_23_2","first-page":"A3","article-title":"Randomized double\u2010blind vehicle\u2010controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis","volume":"125","author":"Warshaw E","year":"2005","journal-title":"J Invest Dermatol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90690-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.08.015"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2007.03145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2007.03145.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:37:42Z","timestamp":1696883862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2007.03145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1365-4632.2007.03145.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03145.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"2007-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}